Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Mint6d
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it will be good enough to retake the lead from rival Eli Lilly ...
Daily Mail6d
Patients who took Ozempic 2.0 in clinical trial reveal its staggering results... and terrifying side effects
fatigue and brain fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave bed. She has, however, kept to the recommended dosing protocol ...
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...